Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma

References

• Li P, Znaor A, Holcatova I, et al. Regional geographic variations in kidney cancer incidence rates in European countries. Eur Urol. 2015;67:1134–1141. doi:10.1016/j.eururo.2014.11.00125465966
   PubMed Web of Science ®Google Scholar
• Kabaria R, Klaassen Z, Terris MK. Renal cell carcinoma: links and risks. Int J Nephrol Renovasc Dis. 2016;9:45–52. doi:10.2147/IJNRD.S7591627022296
   PubMed Web of Science ®Google Scholar
• Brugarolas J. Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 2014;32:1968–1976. doi:10.1200/JCO.2012.45.200324821879
   PubMed Web of Science ®Google Scholar
• Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23:1028–1043. doi:10.1200/JCO.2005.01.18615534359
   PubMed Web of Science ®Google Scholar
• Colombo JR Jr., Haber GP, Jelovsek JE, et al. Seven years after laparoscopic radical nephrectomy: oncologic and renal functional outcomes. Urology. 2008;71:1149–1154. doi:10.1016/j.urology.2007.11.08118313111
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66:290–308. doi:10.3322/caac.2134026910411
   PubMed Web of Science ®Google Scholar
• Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med. 1998;338:1272–1278. doi:10.1056/NEJM1998043033818059562581
   PubMed Web of Science ®Google Scholar
• Rohrmann K, Staehler M, Haseke N, et al. Immunotherapy in metastatic renal cell carcinoma. World J Urol. 2005;23:196–201. doi:10.1007/s00345-004-0470-415806434
   PubMed Web of Science ®Google Scholar
• Rodriguez-Vida A, Hutson TE, Bellmunt J, et al. New treatment options for metastatic renal cell carcinoma. ESMO Open. 2017;2:e000185. doi:10.1136/esmoopen-2017-00018528761748
   PubMed Web of Science ®Google Scholar
• Grunwald V, Karakiewicz PI, Bavbek SE, et al. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer. 2012;48:324–332. doi:10.1016/j.ejca.2011.06.05421803569
   PubMed Web of Science ®Google Scholar
• Cella D, Cappelleri JC, Bushmakin A, et al. Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa. J Oncol Pract. 2009;5:66–70. doi:10.1200/JOP.092200420856722
   PubMedGoogle Scholar
• Yalcin S, Yildiz R, Dane F, et al. A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES study. Onco Targets Ther. 2018;11:1223–1228. doi:10.2147/OTT.S14891729551901
   PubMed Web of Science ®Google Scholar
• Erman M, Benekli M, Basaran M, et al. Renal cell cancer: overview of the current therapeutic landscape. Expert Rev Anticancer Ther. 2016;16:955–968. doi:10.1080/14737140.2016.122290827548347
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134. doi:10.1056/NEJMoa06065517215530
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124. doi:10.1056/NEJMoa06504417215529
   PubMed Web of Science ®Google Scholar
• Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009;101:1717–1723. doi:10.1038/sj.bjc.660536619844230
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8:975–984. doi:10.1016/S1470-2045(07)70285-117959415
   PubMed Web of Science ®Google Scholar
• Gross-Goupil M, Francois L, Quivy A, et al. Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol. 2013;7:269–277. doi:10.4137/CMO.S1059424250243
   PubMedGoogle Scholar
• Nakamura K, Taguchi E, Miura T, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006;66:9134–9142. doi:10.1158/0008-5472.CAN-05-429016982756
   PubMed Web of Science ®Google Scholar
• Hutson TE, Bukowski RM, Rini BI, et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 2014;110:1125–1132. doi:10.1038/bjc.2013.83224434434
   PubMed Web of Science ®Google Scholar
• Eskens FA, de Jonge MJ, Bhargava P, et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, −2, and −3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res. 2011;17:7156–7163. doi:10.1158/1078-0432.CCR-11-041121976547
   PubMed Web of Science ®Google Scholar
• Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol. 2009;27:3225–3234. doi:10.1200/JCO.2008.19.983619470934
   PubMed Web of Science ®Google Scholar
• Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol. 2012;30:1678–1685. doi:10.1200/JCO.2011.35.352422493422
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505–2512. doi:10.1200/JCO.2005.03.672316636341
   PubMed Web of Science ®Google Scholar
• Hutson TE, Davis ID, Machiels JP, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010;28:475–480. doi:10.1200/JCO.2008.21.699420008644
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–3590. doi:10.1200/JCO.2008.20.129319487381
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31:3791–3799. doi:10.1200/JCO.2012.47.494024019545
   PubMed Web of Science ®Google Scholar
• Molina AM, Hutson TE, Nosov D, et al. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. Eur J Cancer. 2018;94:87–94. doi:10.1016/j.ejca.2018.02.00929547835
   PubMed Web of Science ®Google Scholar
• Kim ES. Tivozanib: first global approval. Drugs. 2017;77:1917–1923. doi:10.1007/s40265-017-0825-y28971328
   PubMed Web of Science ®Google Scholar
• Rini BI, Atkins MB, Escudier BJ, et al. Tivo-3: a phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Am Soc Clin Oncol. 2017;35:TPS4600–TPS4600. doi:10.1200/JCO.2017.35.15_suppl.TPS4600
   Google Scholar
• Powles T, Plimack ER, Stus V, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. Am Soc Clin Oncol. 2019;37:543. doi:10.1200/JCO.2019.37.7_suppl.543
   Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–1068. doi:10.1200/JCO.2009.23.976420100962
   PubMed Web of Science ®Google Scholar
• Powles T, Larkin JMG, Patel P, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). J Clin Oncol. 2019;37(suppl 7; abstr 545):545. doi:10.1200/JCO.2019.37.7_suppl.545
   Web of Science ®Google Scholar